Non-receptor tyrosine kinase signaling pathways and therapeutic implications.

Signal Transduct Target Ther · 2026 · PMC13272830 · PMID 42303626

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The results showed a trend towards clinical improvement and significant reductions in inflammatory markers. 362 Another drug that targets the B-cell signaling pathway by acting on the BTK inhibition is Evobrutinib, which is being primarily investigated for autoimmune diseases like MS, Rheumatoid arthritis, and SLE.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.